NCT04565717 - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 9, 2020

Primary Completion Date

January 6, 2023

Study Completion Date

December 21, 2023

Conditions

Nonalcoholic SteatohepatitisNASH

Interventions

DRUG

ALN-HSD

ALN-HSD will be administered by subcutaneous (SC) injection.

DRUG

Placebo

Normal saline (0.9% NaCl) matching volume of ALN-HSD doses will be administered SC.

Trial Locations (13)

Clinical Trial Site, Baltimore

Clinical Trial Site, Fleming Island

Clinical Trial Site, Hermitage

Clinical Trial Site, Marrero

Clinical Trial Site, San Antonio

Clinical Trial Site, San Antonio

Clinical Trial Site, San Antonio

Clinical Trial Site, Brussels

Clinical Trial Site, Sofia

Clinical Trial Site, Balçova

Clinical Trial Site, Izmir

Clinical Trial Site, Edinburgh

Clinical Trial Site, London